- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency | 4 | Benzinga.com | ||
| Di | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| VIRAX BIOLABS GROUP Aktie jetzt für 0€ handeln | |||||
| 30.01. | Virax Biolabs Group Ltd - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 23.01. | Cosmos Health Inc.: Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait | 346 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 13.01. | Cosmos Health announces distribution agreement with Virax Biolabs | 3 | Seeking Alpha | ||
| 13.01. | Cosmos Health Inc.: Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries | 306 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 17.12.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.12.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.12.24 | Virax Biolabs: Interview With COO Nigel McCracken About The Diagnostics And Detection Company | 1 | pulse2.com | ||
| 20.11.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.10.24 | Virax Biolabs announces 2024 annual meeting | 2 | Investing.com | ||
| 31.10.24 | Virax Biolabs kündigt Jahreshauptversammlung 2024 an | - | Investing.com Deutsch | ||
| 31.10.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.10.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.10.24 | Virax Biolabs Signs Distribution Agreement With Europa Biosite To Sell ImmuneSelect; Stock Up | 2 | RTTNews | ||
| 23.10.24 | Virax Biolabs partners with Europa Biosite for UK, Ireland | 1 | Investing.com | ||
| 23.10.24 | Virax Biolabs schließt Partnerschaft mit Europa Biosite für Großbritannien und Irland | 3 | Investing.com Deutsch | ||
| 23.10.24 | EXCLUSIVE: Virax Biolabs Inks Distribution Pact To Commercialize ImmuneSelect Profiling Solutions In UK And Ireland | 1 | Benzinga.com | ||
| 30.09.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.09.24 | Cosmos Health Inc: Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits | 214 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 107,60 | +0,75 % | BioNTech SE: BioNTech veröffentlicht am 10. März 2025 Ergebnisse für das vierte Quartal und das Geschäftsjahr 2024 und informiert über operativen Fortschritt | MAINZ, Deutschland, 24. Februar 2025(Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Montag, den 10. März 2025, die Ergebnisse für das vierte Quartal und das Geschäftsjahr 2024 veröffentlichen.... ► Artikel lesen | |
| EVOTEC | 8,150 | -0,43 % | Kurs von Evotec steigt etwas (8,85 €) | Die Evotec-Aktie notiert heute fester. Das Papier kostete zuletzt 8,85 Euro. Am Aktienmarkt liegt die Evotec-Aktie zur Stunde im Plus. Die Aktie legte um 33 Cent zu. Aktuell wird das Wertpapier an der... ► Artikel lesen | |
| BAVARIAN NORDIC | 21,870 | -4,91 % | Bavarian Nordic A/S: Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older | First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets in the first half of 2025.
COPENHAGEN, Denmark, February 28, 2025... ► Artikel lesen | |
| ASEP MEDICAL | 0,050 | +5,04 % | ASEP Medical Holdings Inc: ASEP to issue 6.77 million shares for debt of $440,585 | ||
| EMERGENT BIOSOLUTIONS | 6,442 | -10,78 % | Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results | ||
| GINKGO BIOWORKS | 8,150 | +1,88 % | Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results | Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an... ► Artikel lesen | |
| GENPREX | 1,820 | -100,00 % | Genprex, Inc.: Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa Gene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer | Expects to Complete Enrollment of First 25 Patients in Phase 2 Expansion Study During Second Half of 2025 for Interim Analysis
Acclaim-3 Study Has FDA Orphan Drug... ► Artikel lesen | |
| PALISADE BIO | 0,840 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis | Data presented at the 2025 Crohn's and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company... ► Artikel lesen | |
| GRITSTONE BIO | 0,016 | -100,00 % | Gritstone bio, Inc. - 8-K, Current Report | ||
| SIGA TECHNOLOGIES | 5,380 | -1,91 % | SIGA Technologies Inc.: TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses | Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno Pharma Co., Ltd. engaged as exclusive distributor... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | Nitches, inc: Nitches Inc. Updates Shareholders on Amazon Integration, GovX Integration, and 2025 Growth Strategy for InTheZone Labs | LAS VEGAS, NV / ACCESSWIRE / December 18, 2024 / Nitches Inc. (OTC PINK:NICH) is pleased to share key updates regarding the recent strides made with its InTheZone Labs brand, highlighting successful... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,071 | -49,28 % | Syros Pharmaceuticals, Inc. Announces Voluntary Delisting from Nasdaq and SEC Deregistration | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed... ► Artikel lesen | |
| ANNOVIS BIO | 1,564 | -11,14 % | Annovis Bio, Inc.: Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease | MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 3,600 | 0,00 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by ... | The planned registration program consists of two double-blind, placebo-controlled multicenter Phase 3 trials, FASCINATE-3 and FASCINIT, to evaluate the safety and efficacy of denifanstat in patients... ► Artikel lesen | |
| HUMACYTE | 3,055 | -10,01 % | Humacyte, Inc: Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025 |
Das Unternehmen VIRAX BIOLABS GROUP LIMITED kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,660 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIRAX BIOLABS GROUP LIMITED finden Sie auf Wallstreet Online.
